Liquid pharmaceutical composition for the delivery of active ingredients

Patent metadata

Field	Value
Publication number	US-11160865-B2
Application number	US-201815945587-A
Country	US
Kind code	B2
Filing date	Apr 4, 2018
Priority date	Oct 20, 2010
Publication date	Nov 2, 2021
Grant date	Nov 2, 2021

Abstract

The invention provides novel pharmaceutical compositions based on semifluorinated alkanes which are useful as carriers for a broad range of active ingredients. Preferred active ingredients include poorly water-soluble and/or hydrolytically sensitive drug substances. The compositions are designed as suspensions and have superior physical properties which make them highly useful as pharmaceutical delivery systems. The compositions may be administered topically into the eye, or injected via the subcutaneous or intramuscular route. The invention further provides kits comprising such compositions.

First claim

The invention claimed is:

1. A pharmaceutical composition in the form of a suspension comprising a dispersed phase in a liquid continuous phase wherein:
(a) the dispersed phase comprises solid particles of an active ingredient, said active ingredient is selected from the group consisting of antibiotic agents, antifungal agents, corticoid, non-steroidal anti-inflammatory agents, and antiviral agents, said active ingredient being present in a therapeutically effective amount, and
(b) the liquid continuous phase comprises a liquid vehicle comprising a semifluorinated alkane of formula RFRH, wherein RF is a linear perfluorinated hydrocarbon segment with 3 to 10 carbon atoms, and wherein RH is a linear alkyl group with 3 to 10 carbon atoms;

wherein the composition is substantially free of water, and wherein the particles of the active ingredient have a volume mean diameter as measured by laser diffraction of not more than 15 μm.

2. The composition of claim 1 , wherein the particles of the active ingredient have a volume mean diameter as measured by laser diffraction of about 2 to about 10 μm.

3. The composition of claim 1 , wherein the active ingredient is an antibiotic agent selected from ofloxacin, ciprofloxacin, levofloxacin, lomefloxacin, moxifloxacin, gentamycin, tobramycin, chloramphenicol, polymyxin B, neomycin, kanamycin, erythromycin, and fusidic acid.

4. The composition of claim 1 , wherein the active ingredient is the antifungal agent amphotericin B.

5. The composition of claim 1 , wherein the active ingredient is a corticoid selected from fluorometholone, prednisolone, and dexamethasone.

6. The composition of claim 1 , wherein the active ingredient is an anti-inflammatory agent selected from ibuprofen, indomethacin, and flurbiprofen.

7. The composition of claim 1 , wherein the active ingredient is the anti-viral agent ganciclovir.

8. The composition of claim 1 , wherein the suspension remains substantially homogenous and finely dispersed for at least 30 minutes after shaking.

9. The composition of claim 1 , being substantially free of a surfactant.

10. The composition of claim 1 , wherein the composition comprises a total amount of surfactant of not more than about 5 wt.-%.

11. The composition of claim 1 , wherein the active ingredient is a poorly water-soluble drug substance and/or sensitive to hydrolytic degradation.

12. The composition of claim 1 , wherein the active ingredient exhibits a water solubility of less than about 1 mg per ml, as measured at room temperature and neutral pH.

13. The composition of claim 1 , wherein the semifluorinated alkane is selected from F4H5 and F6H8.

14. The composition of claim 1 , wherein the composition is adapted for topical ophthalmic administration to an eye of a patient.

15. The composition of claim 1 , wherein the semifluorinated alkane is selected from F4H5, F4H6, F6H6 and F6H8.

16. A pharmaceutical composition in the form of a suspension comprising a dispersed phase in a liquid continuous phase wherein:
(a) the dispersed phase comprises solid particles of an active ingredient, said active ingredient is selected from the group consisting of antibiotic agents, antifungal agents, corticoid, non-steroidal anti-inflammatory agents, and antiviral agents, said active ingredient being present in a therapeutically effective amount, and
(b) the liquid continuous phase comprises a liquid vehicle comprising a semifluorinated alkane of formula RFRH, wherein RF is a linear perfluorinated hydrocarbon segment with 3 to 10 carbon atoms, and wherein RH is a linear alkyl group with 3 to 10 carbon atoms;

wherein the composition is substantially free of water, wherein the composition further comprises a non-fluorinated organic liquid, and wherein the particles of the active ingredient have a volume mean diameter as measured by laser diffraction of not more than 15 μm.

17. The composition of claim 16 , wherein the non-fluorinated organic liquid is an oil or an organic solvent; optionally wherein the oil is selected from the group consisting of a glyceride oil, a liquid wax or a liquid paraffin.

18. The composition of claim 16 , wherein the active ingredient is an antibiotic agent selected from ofloxacin, ciprofloxacin, levofloxacin, lomefloxacin, moxifloxacin, gentamycin, tobramycin, chloramphenicol, polymyxin B, neomycin, kanamycin, erythromycin, and fusidic acid; or a corticoid selected from fluorometholone, prednisolone, and dexamethasone; or an anti-inflammatory agent selected from ibuprofen, indomethacin, and flurbiprofen; or the antifungal agent amphotericin B; or the anti-viral agent ganciclovir.

19. The composition of claim 16 , wherein the particles of the active ingredient have a volume mean diameter as measured by laser diffraction of about 2 to about 10 μm.

20. The composition of claim 16 , wherein the semifluorinated alkane is selected from F4H5, F4H6, F6H6 and F6H8, or wherein the semifluorinated alkane is selected from F4H5 and F6H8.

21. The composition of claim 1 , wherein the semifluorinated alkane has a refractive index in the range of 1.29 to 1.35 at 20° C.

22. The composition of claim 1 , wherein the semifluorinated alkane is selected from F4H4, F4H5, F4H6, F4H7, F4H8, F6H4, F6H6, F6H7, F6H8, F6H9, and F6H10.

Assignees

• Theisinger Bastian
• Theisinger Sonja
• Guenther Bernhard
• Novaliq Gmbh

Inventors

• Theisinger Bastian
• Theisinger Sonja
• Günther Bernhard

Classifications

• A61K9/0046

  Ear · CPC title

• A61K47/24

  containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids · CPC title

• A61K9/0043

  Nose · CPC title

• A61K9/10 Primary

  Dispersions; Emulsions · CPC title

• A61K9/0048

  Eye, e.g. artificial tears · CPC title